Myriad Genetics, Inc., has provided an unrestricted educational grant to the American Medical Association that was used to prepare and distribute up to 75,000 physician education modules on hereditary colon cancer, entitled, ``Identifying and Managing Risk for Hereditary Nonpolyposis Colorectal Cancer and Endometrial Cancer (HNPCC),'' the Company announced today. The education modules provide physicians with up to three hours of AMA PRA Category 1 Continuing Medical Education (CME) credit upon completion.
``Myriad funded a similar program with the AMA on hereditary breast and ovarian cancer that was very successful,'' said Gregory Critchfield, MD, President of Myriad Genetic Laboratories, Inc., the Company's wholly owned predictive medicine subsidiary. ``The AMA has now introduced educational modules on the hereditary aspects of four of the leading cancers among women, representing over 300,000 new cases annually of breast, ovarian, endometrial and colon cancer in the United States alone.''
The AMA co-developed the CME monograph with the American Gastroenterological Association, to create an educational module explaining the basis of hereditary colon cancer. The module contains a review of the genetics of hereditary colon and endometrial (uterine) cancer and the risks associated with hereditary gene mutations, as well as discussion of the clinical and pathological features of the disease. A comprehensive treatment of genetic evaluation of patients with guidelines for appropriate patient selection and interpretation of results complements the information on implications for medical care of patients with a heightened risk of hereditary colon and endometrial cancer.
The educational module will be presented to over 15,000 physicians attending the Digestive Disease Week 2001 conference in Atlanta, GA. Additionally, the AMA has mailed the module to over 32,000 physicians who requested the material prior to its initial printing, and expects to distribute the entire first printing of 75,000 modules in the near future.
Any products appearing in the CME monographs are given for informational purposes only. Their inclusion does not imply AMA or AGA endorsement, nor does omission of any product indicate AMA or AGA disapproval.
Myriad Genetics, Inc. is a biopharmaceutical company focused on the development of novel therapeutic products derived from its proprietary genomic and proteomic technologies.